Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2017 16:05 ET | Source: Selecta Biosciences

Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update

On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017Licensed LMB-100, a Clinical-Stage Candidate for Mesothelioma and Pancreatic Cancer, from the National Cancer Institute...
May 11, 2017 16:01 ET | Source: Selecta Biosciences

Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention

Selecta Applies SVP™ Technology for Immune Stimulation to Address Significant Public Health IssueProgram Being Funded Primarily by U.S. National Institutes of Health (NIH) WATERTOWN, Mass., May 11,...
May 04, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017

WATERTOWN, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
May 02, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers

NCI Currently Conducting Clinical Trials with LMB-100LMB-100 and SVP-Rapamycin Combination Treatment Enhances Anti-Tumor Activity in Preclinical Models Selecta and NCI in Discussions Regarding Phase...
May 01, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy

WATERTOWN, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies that avoid unwanted...
April 26, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Present at Two Upcoming Investor Conferences in May

WATERTOWN, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
March 28, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Present at the Needham Healthcare Conference on April 4, 2017

WATERTOWN, Mass., March 28, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
March 27, 2017 16:01 ET | Source: Selecta Biosciences

Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update

New Data from Ongoing SEL-212 Phase 2 Trial Show Persistent Clinical Activity After Repeat Administration in Symptomatic Gout Patients Emerging Clinical and Preclinical Data Confirm the Broad...
March 20, 2017 08:00 ET | Source: Selecta Biosciences

Selecta Biosciences to Report Fourth Quarter and Year End 2016 Financial Results on Monday, March 27, 2017

WATERTOWN, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on developing biologic therapies for rare and serious...
February 16, 2017 07:00 ET | Source: Selecta Biosciences

Lonza and Selecta Biosciences Announce Manufacturing Agreement for Anc80-AAV-Based Gene Therapy for Treatment of Methylmalonic Acidemia

BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc....